Plasma pentosidine levels in uremic patients before and after hemodialysis. 1995

M Takahashi, and K Kushida, and C Ishihara, and M Denda, and T Inoue
Department of Orthopedic Surgery, Hamamatsu University School of Medicine, Shizuoka, Japan.

Pentosidine, a fluorescent cross-link, is one of the advanced glycosylation end-products. It accumulates in human tissues, plasma and urine in diabetic and uremic patients. Using SP-Sephadex C-25 in the pretreatment for reversed-phase HPLC, we determined pentosidine levels in plasma before and after hemodialysis using cuprophane membranes from 18 patients (9 diabetic, 9 nondiabetic) with end-stage renal disease, as well as examined the hemodialysis efficiency of plasma pentosidine. We also measured beta 2-microglobulin levels in plasma before and after hemodialysis. The values of plasma pentosidine did not significantly change after hemodialysis. Also, plasma beta 2-microglobulin was not removed by hemodialysis. Hemodialysis efficiency of plasma pentosidine and beta 2-microglobulin was nil. In addition, there was a significant correlation between plasma levels of pentosidine and beta 2-microglobulin before hemodialysis in 116 uremic patients. The results indicated that hemodialysis could not eliminate pentosidine from plasma; therefore, pentosidine retention by the diseased kidney might be a major cause of elevated levels of pentosidine with uremia.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008239 Lysine An essential amino acid. It is often added to animal feed. Enisyl,L-Lysine,Lysine Acetate,Lysine Hydrochloride,Acetate, Lysine,L Lysine
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D003432 Cross-Linking Reagents Reagents with two reactive groups, usually at opposite ends of the molecule, that are capable of reacting with and thereby forming bridges between side chains of amino acids in proteins; the locations of naturally reactive areas within proteins can thereby be identified; may also be used for other macromolecules, like glycoproteins, nucleic acids, or other. Bifunctional Reagent,Bifunctional Reagents,Cross Linking Reagent,Crosslinking Reagent,Cross Linking Reagents,Crosslinking Reagents,Linking Reagent, Cross,Linking Reagents, Cross,Reagent, Bifunctional,Reagent, Cross Linking,Reagent, Crosslinking,Reagents, Bifunctional,Reagents, Cross Linking,Reagents, Cross-Linking,Reagents, Crosslinking
D003928 Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE. Diabetic Glomerulosclerosis,Glomerulosclerosis, Diabetic,Diabetic Kidney Disease,Diabetic Nephropathy,Intracapillary Glomerulosclerosis,Kimmelstiel-Wilson Disease,Kimmelstiel-Wilson Syndrome,Nodular Glomerulosclerosis,Diabetic Kidney Diseases,Glomerulosclerosis, Nodular,Kidney Disease, Diabetic,Kidney Diseases, Diabetic,Kimmelstiel Wilson Disease,Kimmelstiel Wilson Syndrome,Nephropathies, Diabetic,Nephropathy, Diabetic,Syndrome, Kimmelstiel-Wilson
D006031 Glycosylation The synthetic chemistry reaction or enzymatic reaction of adding carbohydrate or glycosyl groups. GLYCOSYLTRANSFERASES carry out the enzymatic glycosylation reactions. The spontaneous, non-enzymatic attachment of reducing sugars to free amino groups in proteins, lipids, or nucleic acids is called GLYCATION (see MAILLARD REACTION). Protein Glycosylation,Glycosylation, Protein
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001120 Arginine An essential amino acid that is physiologically active in the L-form. Arginine Hydrochloride,Arginine, L-Isomer,DL-Arginine Acetate, Monohydrate,L-Arginine,Arginine, L Isomer,DL Arginine Acetate, Monohydrate,Hydrochloride, Arginine,L Arginine,L-Isomer Arginine,Monohydrate DL-Arginine Acetate

Related Publications

M Takahashi, and K Kushida, and C Ishihara, and M Denda, and T Inoue
January 2005, Blood purification,
M Takahashi, and K Kushida, and C Ishihara, and M Denda, and T Inoue
July 1975, Thrombosis research,
M Takahashi, and K Kushida, and C Ishihara, and M Denda, and T Inoue
November 1979, Clinical nephrology,
M Takahashi, and K Kushida, and C Ishihara, and M Denda, and T Inoue
June 1975, Clinica chimica acta; international journal of clinical chemistry,
M Takahashi, and K Kushida, and C Ishihara, and M Denda, and T Inoue
January 1989, Cardiovascular drugs and therapy,
M Takahashi, and K Kushida, and C Ishihara, and M Denda, and T Inoue
February 1966, Archives of surgery (Chicago, Ill. : 1960),
M Takahashi, and K Kushida, and C Ishihara, and M Denda, and T Inoue
January 2012, Clinical and experimental hypertension (New York, N.Y. : 1993),
M Takahashi, and K Kushida, and C Ishihara, and M Denda, and T Inoue
January 2016, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
M Takahashi, and K Kushida, and C Ishihara, and M Denda, and T Inoue
January 2004, Journal of nephrology,
M Takahashi, and K Kushida, and C Ishihara, and M Denda, and T Inoue
June 2012, Clinical and experimental nephrology,
Copied contents to your clipboard!